What it is
Ribosomal frameshifting, in which the ribosome shifts its reading frame and translates a different sequence, is an uncommon recoding event best known for its regulatory role in viral gene expression; what it does in mammals is poorly understood. The authors show that specific codon pairs trigger efficient minus-one frameshifting preferentially in cancer cells. Mechanistically, the recoding arises from ribosomal pausing linked to the availability of transfer RNA and amino acids, and is amplified by impaired ribosome quality control and by sustained phosphorylation of the ribosomal protein S6. They describe this codon-pair-specific frameshifting as an intrinsic state of translational dysregulation that is prevalent across cancer cells and reshapes protein synthesis. Exploiting it, they engineered a frameshifting-activated synthetic therapeutic circuit (FAST) that conditionally expresses gasdermin D, a protein that drives pyroptosis, an inflammatory form of cell death. FAST is activated across diverse cancer cell types, inducing potent and selective pyroptosis while sparing normal tissues from detectable toxicity. As a proof of concept, delivering FAST through the whole body with an AAV9 viral vector in mouse models of colorectal and pancreatic cancer produced pronounced tumour regression, immune activation and synergy with immune checkpoint blockade.
Why it matters
A quirk of how cancer cells read their own genetic code becomes the switch that turns a therapy on preferentially inside them, rather than relying on a cancer-specific target protein. Because the circuit responds to a translational state the authors find prevalent across cancer cells, it is not tied to one tumour type, and the abstract reports it working across diverse cancer cell types and in two mouse cancer models. The authors frame it as establishing translation-coupled gene circuits as a strategy for cancer-selective therapy.
Every metric behind this entry is listed, with its source, under Sources and data below.
Filed underRNA and protein synthesis mechanisms, Bacterial Cancer Therapy, RNA modifications and cancer
